Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Understanding the immune responses after secondary vaccinations with Pfizer and Moderna vaccines

In a new study, researchers assessed the serological responses to secondary booster doses of Pfizer's Comirnaty and Moderna's Spikevax COVID-19 vaccines.

23 Feb 2022

Study proposes SARS-CoV-2-encoded peptide presented by HLA-E may suppress inhibition of natural killer cells

A recent study reported the abrogation of inhibition of the NK cells by a SARS-CoV-2-encoded protein presented by HLA-E.

23 Feb 2022

Study explores the impact of COVID-19 on pancreatic cells

New study findings showed that SARS-CoV-2 caused a productive yet restricted infection of pancreatic islet cells and an insignificant inflammatory response.

23 Feb 2022

Cardiopulmonary limitations six months after surviving COVID-19

A recent prospective cohort study assessed the cardiopulmonary effects in patients six months after COVID-19 infection.

23 Feb 2022

Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment

A phase 3 randomized clinical trial has recently been conducted to investigate the efficacy of a capsule formulation in treating mild-to-moderate COVID-19 patients.

23 Feb 2022

Study shows BCG vaccine provides no protection against SARS-CoV-2 in mice and hamsters

Researchers investigated the effectiveness of the BCG vaccines against SARS-CoV-2 infections using three animal models.

23 Feb 2022

SARS-Cov-2 reinfection in Syrian hamsters does not result in disease

Researchers have been investigating the reinfection of different SARS-CoV-2 variants in Syrian hamsters and found that this does not seem to result in disease or any significant pulmonary pathology.

23 Feb 2022

High nasopharyngeal viral load in SARS-CoV-2 Omicron-induced infection

In a recent study posted to the Research Square* pre-print server, a team of researchers from Italy and the United States (US) retrospectively reviewed and compared viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron and previous SARS-CoV-2 strain-induced infection.

23 Feb 2022

More evidence vaccines prevent ICU admission and mortality from SARS-CoV-2

In a recent study posted to the medRxiv* preprint server, researchers estimated the comparative virulence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between the vaccinated and unvaccinated subjects hospitalized with coronavirus disease 2019 (COVID-19) in Canada.

23 Feb 2022

Closing bars and restaurants does not appear to have suppressed COVID-19 in Japan

In a recent study posted in the Research Square* preprint server, which is under consideration at the journal Scientific Reports, a team of researchers conducted a longitudinal survey in 11 Japanese prefectures to evaluate whether early closure of full-service restaurants and bars reduced the incidence and symptoms of coronavirus disease 2019 (COVID-19) during February 2021.

23 Feb 2022

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

23 Feb 2022

Neural mechanisms of fatigue in COVID-19 convalescents

In a recent study posted to the medRxiv* preprint server, researchers characterized the mechanisms associated with neural dysregulation in post-coronavirus disease (COVID) fatigue (pCF) by evaluating individuals recovered from mild severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

23 Feb 2022

SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

In a recent study posted to the medRxiv* pre-print server, researchers performed genomic monitoring to estimate the magnitude and range of the different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in SARS-CoV-2 reinfection cases among fully vaccinated individuals in Salvador, Bahia, Brazil.

23 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Circulating miR-155 may predict chances of survival in hospitalized COVID-19 patients

Scientists from Israel have recently estimated the levels of circulating microRNAs (miRNAs) in hospitalized coronavirus disease 2019 (COVID-19) patients with the aim of identifying prognostic biomarkers for disease severity. They have identified miR-155, an important regulatory molecule in the immune system, as a potential biomarker to predict COVID-19 severity and mortality.

22 Feb 2022

Omicron neutralizing titers after third BNT162b2 dose are persistent

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine.

22 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022